Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 17/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 16/20 | 0.43 |
| ▸ | CDK4 | P11802 | 4/20 | 0.43 |
| ▸ | CCND1 | P24385 | 4/20 | 0.43 |
| ▸ | CDK7 | P50613 | 3/20 | 0.43 |
| ▸ | CCNH | P51946 | 2/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 4/20 | 0.38 |
| ▸ | CDK13 | Q14004 | 2/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.37 |
| ▸ | CDK3 | Q00526 | 2/20 | 0.37 |
| ▸ | CCNK | O75909 | 1/20 | 0.37 |
| ▸ | CDK14 | O94921 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12584740 | 0.81 | CDK9 (0.46) | CDK9CCNT1CDK4CCND1CDK7 | |
| SCHEMBL12584677 | 0.80 | MAPKAPK2 (0.39) | CDK9CCNT1CDK4CCND1CDK7 | |
| SCHEMBL20557978 | 0.77 | AHR (0.48) | — | |
| SCHEMBL19526842 | 0.74 | PRKAB2 (0.38) | CDK9CDK7MAPKAPK2CDK2CDK13 | |
| SCHEMBL12769217 | 0.74 | METAP2 (0.42) | CDK9CCNT1CDK4CCND1CDK2 | |
| SCHEMBL1071726 | 0.73 | PDE10A (0.37) | CDK9CCNT1 | |
| SCHEMBL12584676 | 0.72 | KCNN3 (0.33) | — | |
| SCHEMBL30443346 | 0.72 | SMN1; SMN2 (0.39) | CDK9CCNT1 | |
| SCHEMBL19527077 | 0.71 | KCNN3 (0.33) | — | |
| SCHEMBL12769215 | 0.71 | ALDH1A1 (0.36) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509602-B9 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-11-01 | — | — | EP | disclosed |
| EP-2509602-B9 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-11-01 | — | — | EP | disclosed |
| EP-2509602-B1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-01-25 | — | — | EP | disclosed |
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| EP-2509602-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | Cylene Pharmaceuticals, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2475652-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | Cylene Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011068667-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2011031979-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031979-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | PIM2, PIM1, PIM3 | CDK9 30/4885CCNT1 321/4885CDK4 14/4885 |
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CDK2, CKS2, CSNK2A1 | CDK9 19/4885CCNT1 256/4885CDK4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.